Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more
Amgen Inc (AMGN) - Net Assets
Latest net assets as of December 2025: $8.66 Billion USD
Based on the latest financial reports, Amgen Inc (AMGN) has net assets worth $8.66 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($90.59 Billion) and total liabilities ($81.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $8.66 Billion |
| % of Total Assets | 9.56% |
| Annual Growth Rate | 12.4% |
| 5-Year Change | 29.22% |
| 10-Year Change | -71.02% |
| Growth Volatility | 49.0 |
Amgen Inc - Net Assets Trend (1985–2025)
This chart illustrates how Amgen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amgen Inc (1985–2025)
The table below shows the annual net assets of Amgen Inc from 1985 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $8.66 Billion | +47.32% |
| 2024-12-31 | $5.88 Billion | -5.70% |
| 2023-12-31 | $6.23 Billion | +70.23% |
| 2022-12-31 | $3.66 Billion | -45.36% |
| 2021-12-31 | $6.70 Billion | -28.79% |
| 2020-12-31 | $9.41 Billion | -2.73% |
| 2019-12-31 | $9.67 Billion | -22.62% |
| 2018-12-31 | $12.50 Billion | -50.48% |
| 2017-12-31 | $25.24 Billion | -15.51% |
| 2016-12-31 | $29.88 Billion | +5.90% |
| 2015-12-31 | $28.21 Billion | +9.43% |
| 2014-12-31 | $25.78 Billion | +16.66% |
| 2013-12-31 | $22.10 Billion | +15.93% |
| 2012-12-31 | $19.06 Billion | +0.16% |
| 2011-12-31 | $19.03 Billion | -20.53% |
| 2010-12-31 | $23.94 Billion | +5.63% |
| 2009-12-31 | $22.67 Billion | +11.19% |
| 2008-12-31 | $20.39 Billion | +14.09% |
| 2007-12-31 | $17.87 Billion | -5.77% |
| 2006-12-31 | $18.96 Billion | -7.27% |
| 2005-12-31 | $20.45 Billion | +3.79% |
| 2004-12-31 | $19.70 Billion | +1.30% |
| 2003-12-31 | $19.45 Billion | +6.38% |
| 2002-12-31 | $18.29 Billion | +250.50% |
| 2001-12-31 | $5.22 Billion | +20.92% |
| 2000-12-31 | $4.31 Billion | +42.70% |
| 1999-12-31 | $3.02 Billion | +18.00% |
| 1998-12-31 | $2.56 Billion | +19.77% |
| 1997-12-31 | $2.14 Billion | +12.22% |
| 1996-12-31 | $1.91 Billion | +14.03% |
| 1995-12-31 | $1.67 Billion | +31.19% |
| 1994-12-31 | $1.27 Billion | +8.73% |
| 1993-12-31 | $1.17 Billion | +25.52% |
| 1992-12-31 | $933.70 Million | +75.80% |
| 1991-12-31 | $531.10 Million | +33.44% |
| 1990-12-31 | $398.00 Million | +111.59% |
| 1989-12-31 | $188.10 Million | +16.18% |
| 1988-12-31 | $161.90 Million | -0.98% |
| 1987-12-31 | $163.50 Million | +94.64% |
| 1986-12-31 | $84.00 Million | +4.22% |
| 1985-12-31 | $80.60 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amgen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2508610000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.66 Billion | 100.00% |
| Other Components | $25.11 Billion | 289.99% |
| Total Equity | $8.66 Billion | 100.00% |
Amgen Inc Competitors by Market Cap
The table below lists competitors of Amgen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shopify Inc
NYSE:SHOP
|
$196.50 Billion |
|
Naspers Limited
PINK:NAPRF
|
$198.66 Billion |
|
Linde plc Ordinary Shares
NASDAQ:LIN
|
$210.18 Billion |
|
PepsiCo Inc
NASDAQ:PEP
|
$213.31 Billion |
|
Nextera Energy Inc
NYSE:NEE
|
$192.91 Billion |
|
KLA-Tencor Corporation
NASDAQ:KLAC
|
$192.38 Billion |
|
Citigroup Inc
NYSE:C
|
$192.16 Billion |
|
Abbott Laboratories
NYSE:ABT
|
$191.37 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amgen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,877,000,000 to 8,658,000,000, a change of 2,781,000,000 (47.3%).
- Net income of 7,711,000,000 contributed positively to equity growth.
- Dividend payments of 5,124,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 66,000,000.
- Other factors increased equity by 128,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $7.71 Billion | +89.06% |
| Dividends Paid | $5.12 Billion | -59.18% |
| Other Comprehensive Income | $66.00 Million | +0.76% |
| Other Changes | $128.00 Million | +1.48% |
| Total Change | $- | 47.32% |
Book Value vs Market Value Analysis
This analysis compares Amgen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 22.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2602.73x to 22.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1985-12-31 | $0.14 | $361.13 | x |
| 1986-12-31 | $0.09 | $361.13 | x |
| 1987-12-31 | $0.17 | $361.13 | x |
| 1988-12-31 | $0.20 | $361.13 | x |
| 1989-12-31 | $0.30 | $361.13 | x |
| 1990-12-31 | $0.63 | $361.13 | x |
| 1991-12-31 | $0.49 | $361.13 | x |
| 1992-12-31 | $0.81 | $361.13 | x |
| 1993-12-31 | $1.07 | $361.13 | x |
| 1994-12-31 | $1.13 | $361.13 | x |
| 1995-12-31 | $1.46 | $361.13 | x |
| 1996-12-31 | $1.70 | $361.13 | x |
| 1997-12-31 | $1.95 | $361.13 | x |
| 1998-12-31 | $2.42 | $361.13 | x |
| 1999-12-31 | $2.80 | $361.13 | x |
| 2000-12-31 | $3.98 | $361.13 | x |
| 2001-12-31 | $4.81 | $361.13 | x |
| 2002-12-31 | $15.85 | $361.13 | x |
| 2003-12-31 | $14.40 | $361.13 | x |
| 2004-12-31 | $14.93 | $361.13 | x |
| 2005-12-31 | $16.26 | $361.13 | x |
| 2006-12-31 | $15.94 | $361.13 | x |
| 2007-12-31 | $15.91 | $361.13 | x |
| 2008-12-31 | $18.96 | $361.13 | x |
| 2009-12-31 | $22.20 | $361.13 | x |
| 2010-12-31 | $24.81 | $361.13 | x |
| 2011-12-31 | $20.87 | $361.13 | x |
| 2012-12-31 | $24.22 | $361.13 | x |
| 2013-12-31 | $28.88 | $361.13 | x |
| 2014-12-31 | $33.48 | $361.13 | x |
| 2015-12-31 | $36.66 | $361.13 | x |
| 2016-12-31 | $39.62 | $361.13 | x |
| 2017-12-31 | $34.34 | $361.13 | x |
| 2018-12-31 | $18.80 | $361.13 | x |
| 2019-12-31 | $15.88 | $361.13 | x |
| 2020-12-31 | $15.95 | $361.13 | x |
| 2021-12-31 | $11.69 | $361.13 | x |
| 2022-12-31 | $6.77 | $361.13 | x |
| 2023-12-31 | $11.58 | $361.13 | x |
| 2024-12-31 | $10.86 | $361.13 | x |
| 2025-12-31 | $15.97 | $361.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amgen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 89.06%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.99%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 10.46x
- Recent ROE (89.06%) is above the historical average (33.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1985 | 0.62% | 2.37% | 0.23x | 1.16x | $-7.56 Million |
| 1986 | 0.95% | 2.68% | 0.31x | 1.15x | $-7.60 Million |
| 1987 | 1.04% | 3.84% | 0.23x | 1.18x | $-14.65 Million |
| 1988 | -5.06% | -11.68% | 0.34x | 1.28x | $-24.39 Million |
| 1989 | 10.15% | 10.03% | 0.62x | 1.64x | $290.00K |
| 1990 | 4.80% | 10.03% | 0.37x | 1.29x | $-20.70 Million |
| 1991 | 18.43% | 14.40% | 0.79x | 1.63x | $44.79 Million |
| 1992 | 38.30% | 33.10% | 0.79x | 1.47x | $264.23 Million |
| 1993 | 32.70% | 28.29% | 0.77x | 1.51x | $266.10 Million |
| 1994 | 25.09% | 19.73% | 0.81x | 1.56x | $192.27 Million |
| 1995 | 32.16% | 28.24% | 0.78x | 1.46x | $370.52 Million |
| 1996 | 35.66% | 30.93% | 0.79x | 1.45x | $489.17 Million |
| 1997 | 30.12% | 27.47% | 0.75x | 1.45x | $430.37 Million |
| 1998 | 33.69% | 32.67% | 0.72x | 1.43x | $606.98 Million |
| 1999 | 36.26% | 34.22% | 0.79x | 1.35x | $794.05 Million |
| 2000 | 26.39% | 33.02% | 0.64x | 1.25x | $707.05 Million |
| 2001 | 21.46% | 27.88% | 0.62x | 1.23x | $597.98 Million |
| 2002 | -7.61% | -25.20% | 0.23x | 1.34x | $-3.22 Billion |
| 2003 | 11.65% | 27.04% | 0.32x | 1.35x | $320.59 Million |
| 2004 | 11.99% | 22.40% | 0.36x | 1.48x | $392.50 Million |
| 2005 | 17.96% | 29.56% | 0.42x | 1.43x | $1.63 Billion |
| 2006 | 15.56% | 20.68% | 0.42x | 1.78x | $1.05 Billion |
| 2007 | 17.72% | 21.43% | 0.43x | 1.94x | $1.38 Billion |
| 2008 | 20.58% | 27.97% | 0.41x | 1.79x | $2.16 Billion |
| 2009 | 20.32% | 31.45% | 0.37x | 1.75x | $2.34 Billion |
| 2010 | 19.32% | 30.74% | 0.35x | 1.82x | $2.23 Billion |
| 2011 | 19.35% | 23.64% | 0.32x | 2.57x | $1.78 Billion |
| 2012 | 22.80% | 25.17% | 0.32x | 2.85x | $2.44 Billion |
| 2013 | 23.00% | 27.21% | 0.28x | 2.99x | $2.87 Billion |
| 2014 | 20.01% | 25.71% | 0.29x | 2.68x | $2.58 Billion |
| 2015 | 24.71% | 32.03% | 0.30x | 2.55x | $4.13 Billion |
| 2016 | 25.85% | 33.59% | 0.30x | 2.60x | $4.73 Billion |
| 2017 | 7.84% | 8.66% | 0.29x | 3.17x | $-545.10 Million |
| 2018 | 67.15% | 35.35% | 0.36x | 5.31x | $7.14 Billion |
| 2019 | 81.07% | 33.57% | 0.39x | 6.17x | $6.87 Billion |
| 2020 | 77.20% | 28.57% | 0.40x | 6.69x | $6.32 Billion |
| 2021 | 87.96% | 22.68% | 0.42x | 9.13x | $5.22 Billion |
| 2022 | 178.97% | 24.89% | 0.40x | 17.79x | $6.19 Billion |
| 2023 | 107.78% | 23.83% | 0.29x | 15.59x | $6.09 Billion |
| 2024 | 69.59% | 12.24% | 0.36x | 15.63x | $3.50 Billion |
| 2025 | 89.06% | 20.99% | 0.41x | 10.46x | $6.85 Billion |
Industry Comparison
This section compares Amgen Inc's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $394,499,575,667
- Average return on equity (ROE) among peers: -0.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amgen Inc (AMGN) | $8.66 Billion | 0.62% | 9.46x | $194.15 Billion |
| AbbVie Inc (ABBV) | $15.70 Billion | 26.61% | 0.35x | $387.90 Billion |
| Astellas Pharma Inc (ALPMF) | $1.46 Trillion | 8.50% | 0.60x | $16.93 Billion |
| Amarin Corporation PLC (AMRN) | $24.15 Million | -158.05% | 0.75x | $303.32 Million |
| AstraZeneca PLC (AZN) | $14.91 Billion | 37.51% | 2.22x | $295.24 Billion |
| Bayer AG (BAYZF) | $20.80 Billion | 15.33% | 1.47x | $21.61 Billion |
| Biogen Inc (BIIB) | $6.43 Billion | 19.21% | 0.41x | $27.11 Billion |
| Bristol-Myers Squibb Company (BMY) | $4.75 Billion | 22.46% | 0.58x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $2.03 Trillion | 21.42% | 0.22x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $58.37 Million | 6.18% | 0.57x | $529.97 Million |